Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.
Lee. Byung Wan BW; Lee. Chang Beom CB; Lim. Soo S; Kim. Sin Gon SG; Kim. Nan Hee NH; Won. Jong Chul JC; Lee. Woo Je WJ; Kang. Min Ju MJ; Yuh. Ju Young JY; Du. Li Ying LY; Lim. Hyojin H; Ahn. Kyu Jeung KJ
Key Findings
- HbA1c fell 2.75‑3.25 % across doses
- Body weight dropped 6.8‑10.9 % from baseline
- 84.6‑100 % achieved HbA1c < 7 % and 69.2‑85.2 % hit HbA1c ≤ 6.5 % without weight gain or serious hypoglycaemia
- Safety profile in Koreans matched overall trial data
Practical Outcomes
- Tirzepatide can be a potent, once‑weekly option for major blood‑sugar and weight reductions in T2D, supporting dose‑escalation from 5 mg up to 15 mg based on response. Enthusiasts can use these Korean subgroup results to gauge expected benefits and monitor similar side‑effects, making it a viable protocol for off‑label longevity or metabolic‑health experiments.
Summary
In Korean adults with type 2 diabetes, weekly tirzepatide (5‑15 mg) cut blood‑sugar levels by about 3 % and trimmed body weight by roughly 7‑11 % over 40‑52 weeks, with most people hitting the <7 % HbA1c goal and many reaching ≤6.5 % without gaining weight or severe low‑blood‑sugar episodes. The safety picture matched what’s seen in larger, global studies, so the drug looks both powerful and tolerable for real‑world use.
Abstract
This post hoc analysis assessed the efficacy and safety data in tirzepatide-treated Korean patients with type 2 diabetes (T2D). Data specifically from Korean patients treated with tirzepatide 5, 10, or 15 mg in the multicentre, randomised, open-label, parallel-group, phase 3 trials SURPASS-AP-Combo and SURPASS-3 were extracted and analysed. Efficacy (change from baseline in glycated haemoglobin [HbA1c] and body weight, and proportions of participants achieving HbA1c and body weight targets) and safety endpoints were evaluated at week 40 (SURPASS-AP Combo) and week 52 (SURPASS-3). In the SURPASS-AP-Combo and SURPASS-3, 79 of 687 and 27 of 1079 tirzepatide recipients, respectively, were Korean. In Korean participants in SURPASS-AP-Combo across all tirzepatide doses, least squares mean (LSM) HbA1c was reduced from baseline by 2.75% to 3.25% and HbA1c targets of <7.0% and ≤6.5% were achieved by 84.6% to 100% at week 40; LSM body weight reductions of -6.8% to -10.9% from baseline were achieved. The composite endpoint of HbA1c ≤6.5% without body weight gain or clinically significant documented symptomatic or severe hypoglycaemia was achieved by 69.2% to 85.2% of tirzepatide recipients. Findings were similar in Korean participants of SURPASS-3. The safety profile of tirzepatide in Korean participants was generally consistent with that in the overall SURPASS-AP-Combo and SURPASS-3 populations. Consistent with the overall results of the SURPASS-AP-Combo and SURPASS-3 trials, this post hoc subgroup analysis found clinically meaningful reductions in HbA1c and body weight after treatment periods of 40 to 52 weeks in Koreans with T2D treated with tirzepatide.
Study Information
pubmed
2025
2025-09-15T00:00:00.000Z
10.1111/dom.70111
22